KBC Group’s Beam Therapeutics BEAM Stock Holding History

KBC Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$87K	Hold	3,569	–	–	﹤0.01%	1474
2026 Q2	$122K	Hold	3,569	–	–	﹤0.01%	1292
2026 Q1	$85K	Hold	3,569	–	–	﹤0.01%	1417
2025 Q4	$99K	Hold	3,569	–	–	﹤0.01%	1284
2025 Q3	$87K	Buy	3,569 +1,535	+75%	+$30.5K	﹤0.01%	1347
2025 Q2	$35K	Sell	2,034 -2,109	-51%	-$36.7K	﹤0.01%	1686
2025 Q1	$81K	Hold	4,143	–	–	﹤0.01%	1591
2024 Q4	$103K	Buy	4,143 +2,104	+103%	+$53.7K	﹤0.01%	1536
2024 Q3	$50K	Hold	2,039	–	–	﹤0.01%	1705
2024 Q2	$48K	Buy	2,039 +244	+14%	+$5.99K	﹤0.01%	1643
2024 Q1	$59K	Hold	1,795	–	–	﹤0.01%	1450
2023 Q4	$49K	Buy	1,795 +620	+53%	+$15.4K	﹤0.01%	1536
2023 Q3	$28K	Buy	+1,175	New	+$31.5K	﹤0.01%	1807

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

KBC Group's BEAM Position: Q3 2026 in Review

KBC Group held its Beam Therapeutics (BEAM) position steady in Q3 2026 at 3,569 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1474.

KBC Group first reported a position in BEAM in Q3 2023 and has held it in 13 quarters since. The position peaked at $122K in Q2 2026. 191 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

KBC Group held 3,569 shares of Beam Therapeutics worth $87K as of Q3 2026.
KBC Group left its Beam Therapeutics share count unchanged in Q3 2026.
Beam Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1474 holding.
KBC Group first reported a position in Beam Therapeutics in Q3 2023 and has held it in 13 quarters since.
KBC Group's Beam Therapeutics position peaked at $122K in Q2 2026.
191 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.